Klapper J A, O'Connor S
Colorado Neurology and Headache Center, Denver 80218, USA.
Cephalalgia. 2000 Jul;20(6):585-7. doi: 10.1046/j.1468-2982.2000.00079.x.
Rizatriptan wafer is a 5HT1B/1D agonist for use in the acute treatment of migraine. It is a freeze-fried formulation, approved for oral administration, which dissolves on the tongue and is swallowed with saliva. In this study the efficacy of sublingually administered rizatriptan 10-mg wafer was evaluated in a randomized, double-blind, placebo-controlled, out-patient study involving 39 migraineurs. Patients were instructed to treat a migraine at the onset of pain in order to evaluate time of onset of pain relief and pain relief at 1 h. The average time to onset of relief was 25 min for patients treated with rizatriptan wafer and 27 min for patients treated with placebo. At 1 h, 50% of the patients receiving rizatriptan wafer and 50% of the patients receiving placebo experienced significant relief. Implications and potential reasons for a high placebo response are discussed.
利扎曲普坦片是一种用于偏头痛急性治疗的5HT1B/1D激动剂。它是一种冻干制剂，批准用于口服，可在舌头上溶解并随唾液咽下。在本研究中，对39名偏头痛患者进行了一项随机、双盲、安慰剂对照的门诊研究，评估了舌下含服10毫克利扎曲普坦片的疗效。患者被指示在疼痛发作时治疗偏头痛，以评估疼痛缓解的起效时间和1小时时的疼痛缓解情况。接受利扎曲普坦片治疗的患者缓解起效的平均时间为25分钟，接受安慰剂治疗的患者为27分钟。1小时时，接受利扎曲普坦片的患者中有50%、接受安慰剂的患者中有50%经历了显著缓解。文中讨论了高安慰剂反应的影响及潜在原因。
